Aprea Therapeutics, Inc. (APRE) vs Longeveron Inc. (LGVN)
A side-by-side comparison of Aprea Therapeutics, Inc. and Longeveron Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
APRE
Aprea Therapeutics, Inc.
$0.66HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
LGVN
Longeveron Inc.
$2.41HealthcareDelayed quote: Oct 6, 2026, 10:39 AM EDT
Total return — APRE vs LGVN
growth of $100 · dividends reinvested · last 6yAPRE -99.5% (-59.2%/yr)LGVN -99.7% (-61.2%/yr)APRE compounded faster over this window
APRE LGVN
APRE vs LGVN: by the numbers
- •APRE is the larger company ($8M vs $7M market cap).
- •Both run net losses; APRE's is the smaller (0.00% vs -1977.59% net margin).
Metrics side by side
Valuation
| Metric | APRE | LGVN |
|---|---|---|
| P/S ratio | N/A | 6.18 |
| P/B ratio | 0.21 | 0.71 |
Profitability
| Metric | APRE | LGVN |
|---|---|---|
| Gross margin | 0.00% | 69.76% |
| Operating margin | 0.00% | -1942.20% |
| Net margin | 0.00% | -1977.59% |
| ROE | -31.99% | -225.67% |
| ROIC | -33.73% | -211.58% |
Growth (annualized)
| Metric | APRE | LGVN |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -21.21% |
| Total return CAGR (5Y) | -63.30% | -62.60% |
Frequently asked
- How have APRE and LGVN total returns compared?
- Over the past 5 years, APRE delivered -63.30% and LGVN delivered -62.60% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.